CLOs on the Move

Centura Health

www.centura.org

 
Centura Health connects individuals, families and neighborhoods across Colorado and western Kansas with more than 6,000 physicians and 21,000 of the best hearts and minds in health care. Through our 19 hospitals, neighborhood health centers, physician practices and clinics, home care and hospice services, and Flight For Life® Colorado, our caregivers make the region`s best health care accessible. We`re on a mission to build flourishing communities and whole person care. We`re Centura Health, and we`re your dedicated health partner for life.
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.centura.org
  • 9100 East Mineral Circle
    Centennial, CO USA 80112
  • Phone: 303.290.6500

Executives

Name Title Contact Details
Thomas Donohoe
Senior Vice President and General Counsel Profile
Jennifer England
VP, Assistant General Counsel Profile
Kris Ordelheide
General Counsel Profile
Kris Ordelheide
Senior Vice President and General Counsel Profile

Similar Companies

Regulatory and Clinical Research Institute

Regulatory & Clinical Research Institute is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Boehringer Ingelheim Pharma

Boehringer Ingelheim Pharma Inc. is a Ridgefield, CT-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

miraDry

Make excessive sweat a thing of the past. Learn how miraDry® can permanently reduce underarm sweat in as little as one non-surgical treatment.

ProNAi

ProNAi Therapeutics is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform for patients with cancer and hematological diseases. ProNAi`s lead DNAi product candidate, PNT2258, is designed to treat cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently initiated "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.